| 5.702 -0.158 (-2.7%) | 10-13 11:28 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.09 | 1-year : | 12.96 |
| Resists | First : | 9.5 | Second : | 11.09 |
| Pivot price | 6.3  |
|||
| Supports | First : | 4.5 | Second : | 1.4 |
| MAs | MA(5) : | 5.95 |
MA(20) : | 6.1  |
| MA(100) : | 5.23 |
MA(250) : | 10.89 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 4.3 |
D(3) : | 7.6 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 35.5 | Low : | 1.4 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AEMD ] has closed above bottom band by 7.7%. Bollinger Bands are 69.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.07 - 6.1 | 6.1 - 6.13 |
| Low: | 5.72 - 5.76 | 5.76 - 5.8 |
| Close: | 5.79 - 5.86 | 5.86 - 5.92 |
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Sat, 10 Oct 2026
Aethlon Medical Inc (AEMD-Q) Stock Price and News - The Globe and Mail
Sat, 10 Oct 2026
Aethlon Medical Expands Authorized Common Stock Capacity - The Globe and Mail
Wed, 30 Sep 2026
Aethlon Medical, Inc. (AEMD) Stock Price & News - Syfe
Wed, 23 Sep 2026
Aethlon Medical (NasdaqCM:AEMD) Stock Forecast & Analyst Predictions - Simply Wall Street
Fri, 18 Sep 2026
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD) - PR Newswire
Thu, 17 Sep 2026
$180 million fuels Aethlon Medical (NASDAQ: AEMD) merger built around a new skin-disease antibody - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 4.3 (%) |
| Shares Short | 75 (K) |
| Shares Short P.Month | 462 (K) |
| EPS | -32.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.89 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -76.7 % |
| Return on Equity (ttm) | -161 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.18 |
| PEG Ratio | 0 |
| Price to Book value | 0.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|